KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

NCT07232602 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: MK-3120
DRUG: EV
BIOLOGICAL: Pembrolizumab
DRUG: Rescue Medication

Sponsor

Merck Sharp & Dohme LLC